Our data of heterozygous ATM GVs in 2.9% glioma patients with presumed tumor predisposition corroborate and extend the findings of ATM GVs in 1/152 (0.7%) glioma patients [51] and 3/304 (1.0%) glioma families [15]. This evidence concerns the gene ATM and central nervous system cancer.